Lake Street analyst Frank Takkinen raised the firm’s price target on Inspire Medical to $305 from $250 and keeps a Buy rating on the shares, stating that the company "performed superbly" in its "seasonally strongest quarter of the year." Inspire "remains in the early innings" as indicated by the expectation for continued outsized growth and 2023 year-over-year growth guidance of 37%-40%, Lake Street added.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INSP:
- Inspire Medical price target raised to $330 from $310 at Truist
- Inspire Medical price target raised to $305 from $300 at Piper Sandler
- Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance
- Inspire Medical reports Q4 EPS 10c, consensus (57c)
- Inspire Medical price target raised to $310 from $308 at Truist
